Fujirebio US, Inc.
Malvern, PA Fujirebio Diagnostics, Inc. Part of Abbott Laboratories
- UEI
- QLBVMG7KJ3W5
- CAGE
- 47VE1
- Primary NAICS
- 325413 In-Vitro Diagnostic Substance Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, Abbott Laboratories Inc., ranks:
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
Parent
Green Oaks, IL
EF9EAJ1MF6U3
-
Parent
Green Oaks, IL
EF9EAJ1MF6U3
- SAM.gov registration date
- Physical address
- 205 Great Valley Pkwy, Malvern, PA 19355, USA
- Website
- fujirebio.com
- Founded
- 1950
- Employees
- 251-1K
- Estimated annual revenue
- $100M-$250M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Life Sciences Tools & Services
- SIC code
- 38 Instruments & Related Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $86,094 |
| FY2024 | -$200 |
| FY2023 | $337,383 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Assay kits for lumipulse instrument. | National Institute on Drug Abuse (NIH) | $97,757 | |
| Plasma reagents, calibrators and controls. | National Institute on Drug Abuse (NIH) | $190,372 | |
| Inno-LIA HIV i/II score | CDC Pittsburgh | $24,070 | |
| Inno-LIA HCV score | CDC Pittsburgh | $4,000 | |
| Lumipulse immunoassay system | Veterans Integrated Service Network 20 (VHA) | $118,942 |
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Sekisui Diagnostics, LLC | San Diego, CA | 325413 In-Vitro Diagnostic Substance Manufacturing |
| Labcorp | Englewood, CO | 621511 Medical Laboratories |
| Enzo Life Sciences International Inc. | Farmingdale, NY | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Vela Diagnostics USA Inc. | Fairfield, NJ | 423450 Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers |
| Bio / Data Corp | — | 334516 Analytical Laboratory Instrument Manufacturing |
About the company
Fujirebio US, Inc. is a for-profit, corporate entity registered in SAM.gov since 2005, specializing in medical diagnostics manufacturing and equipment production. As a child entity with a location in Malvern, Pennsylvania, the company focuses on developing advanced medical testing technologies and diagnostic solutions for healthcare and research institutions. The organization is a manufacturer of goods that provides specialized medical diagnostic equipment, reagents, assay kits, and related scientific instruments to federal government agencies.
The company has secured multiple federal contract awards primarily from healthcare-related agencies, including the National Institute on Aging, Centers for Disease Control and Prevention, Department of Veterans Affairs, and National Cancer Institute. These contracts, typically structured as purchase orders, have ranged from $3,999.70 to $190,372.20 and cover a diverse range of diagnostic products. Specific products include INNO-LIA HIV I/II SCORE tests, INNO-LIA HCV SCORE tests, Lumipulse immunoassay systems, plasma reagents, calibrators, controls, and assay kits for quantifying biomarkers related to Alzheimer's disease. None of the contracts have had specific set-aside designations, and they have consistently been awarded as direct purchases to support medical research, public health monitoring, and clinical studies. The contracts demonstrate Fujirebio's expertise in providing cutting-edge diagnostic technologies across various medical domains, with a particular emphasis on neurological disease research and infectious disease testing.
Quick answers
Is Fujirebio US, Inc. registered in SAM.gov?
Yes. Fujirebio US, Inc.'s SAM.gov registration is active through December 16, 2026.
How much has Fujirebio US, Inc. received in federal contracts?
Federal contracts obligated $86,094 to Fujirebio US, Inc. in fiscal year 2025 and $423,277 in fiscal years 2023 through 2027.
How does Fujirebio US, Inc. rank among federal contractors?
Fujirebio US, Inc.'s parent company, Abbott Laboratories Inc., ranked #1 in NAICS 334516, #3 in PSC 6630 and #4 in PSC 6550 in FY2025.
What is Fujirebio US, Inc.'s most recent federal award?
Fujirebio US, Inc.'s most recent federal contract award is Assay kits for lumipulse instrument (75N95025P00106), from National Institute on Drug Abuse (NIH), on February 20, 2025.
On GovTribe
See Fujirebio US, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors